CRISPR Therapeutics AG (CRSP)
| Market Cap | 13.62B |
| Revenue (ttm) | 77.37M |
| Net Income (ttm) | -211.28M |
| Shares Out | 70.14M |
| EPS (ttm) | -3.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $166.58 |
| Previous Close | $169.53 |
| Change ($) | -2.95 |
| Change (%) | -1.74% |
| Day's Open | 161.83 |
| Day's Range | 155.28 - 168.59 |
| Day's Volume | 1,663,711 |
| 52-Week Range | 33.68 - 210.04 |
If you're afraid of a pop, it's best to be prepared.
With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...
CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.
These companies offer some of the most innovative technologies in the life sciences industry.
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...
A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).
Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The...
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Berkshire's best days seem to be behind it, but this investing wiz could be the next Buffett.
The gene-editing stocks are being pulled down by a broader biotech sell-off.
Since the Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for their work on gene editing technology, CRISPR, related stocks have been red hot. CRISPR technol...
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.
Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.
This gene-editing leader's current programs only reveal a hint of what it could become.
It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.
These disruptive biotech stocks could prove to be great investments in the long run.
The battle for beta thalassemia and sickle cell disease patients is heating up.
CRISPR Therapeutics and Vertex Pharmaceuticals released data on 10 patients treated with their investigational CRISPR/Cas9 gene-editing therapy, CTX001, showing durable response to treatment, ...
In the Century of Biology, it pays to own the future of curing disease at the root.
Analysts have been raising their price targets on the stock based on news about a treatment the biotech is developing in partnership with Vertex Pharmaceuticals.
CRISPR Therapeutics AG (CRSP) Phase 1/2 CTX001 Investor Update (Transcript)
Listen in to hear how you can profit in 2021 and beyond
Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.
One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares r...
The stock price of Crispr Therapeutics AG (NASDAQ: CRSP) has increased by 18.98% over the past week. This is why it happened.
- Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -
CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)
Currently, value stocks are mostly value traps, while market leaders are expensive. We have to find diversification elsewhere. Genome editing is a space poised for innovation. The costs are de...
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced th...
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...
Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.
Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock. The post Volatility May Continue, But CRISPR Stock Remains a Buy...
This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments. The post Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-H...
Despite a large 3x rise since the March 23 lows of this year, at the current price of around $107 per share we believe CRISPR Therapeutics stock, a biotechnology gene editing company focused o...
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...
Crispr Therapeutics and Vertex Pharmaceuticals unveiled promising results for a gene-editing approach to blood diseases Wednesday. The news sent CRSP stock flying higher.
CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced da...
Its approach to cell therapy is lucrative and immensely powerful for patients.
The company flipped to a bottom-line loss for the period.
-Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-
Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.
Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX00... [Read more...]
| Industry Biotechnology | IPO Date Oct 19, 2016 |
| CEO Samarth Kulkarni | Employees 304 |
| Stock Exchange NASDAQ | Ticker Symbol CRSP |
Analyst Forecasts
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 146.56, which is a decrease of -12.02% from the latest price.